Prot # CDEB025A2301: A Randomized, Double-blind, Placebo-Controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination with Standard of Care in Hepatitis C Genotype 1 Treatment-nave Patients

Project: Research project

Project Details

StatusFinished
Effective start/end date9/19/119/19/14

Funding

  • Novartis Pharmaceuticals Corporation (CDEB025A2301)